VRTX vs CRSP
VRTX and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $143.39B | $4.93B |
| P/E (TTM) | 32.9 | — |
| P/B | 7.08 | — |
| P/S | 11.9x | 1407.1x |
| Revenue | $12.59B(TTM) | — |
| Revenue growth (YoY) | 8.9% | -90.6% |
| Net income | $4.41B(TTM) | — |
| Earnings growth (YoY) | 838.1% | -58.8% |
| EPS, diluted | $17.17(TTM) | — |
| EBIT margin | 34.8% | -18933.6% |
| ROE | 19.5% | -33.3% |
| ROIC | 25.0% | -32.6% |
| 1y total return | +32.5% | -20.2% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: VRTX vs CRSP
| 지표 | VRTX | CRSP |
|---|---|---|
| 최종 가치 | $68.9K | $36.2K |
| 총수익률 | +589.1% | +262.0% |
| CAGR | +21.2% | +13.7% |
| 변동성 | 32.6% | 63.9% |
| 샤프 | 0.63 | 0.45 |
| 소르티노 | 0.93 | 0.70 |
| 최대 낙폭 | -41.6% | -85.1% |
공통 거래일 2523일 기준, 2016-10-19 → 2026-11-02 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)